Scarica l'app Stockscreener
4.67
6.22%
-0.31
Dopo l'orario di chiusura:
4.71
0.04
+0.86%
Precedente Chiudi:
$4.98
Aprire:
$5.04
Volume 24 ore:
1.36M
Relative Volume:
1.31
Capitalizzazione di mercato:
$342.06M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-2.7633
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
-5.47%
1M Prestazione:
-17.78%
6M Prestazione:
-2.51%
1 anno Prestazione:
-41.18%
Intervallo 1D:
$4.66
$5.09
Intervallo di 1 settimana:
$4.66
$5.295
Portata 52W:
$4.25
$9.08
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.67 | 342.06M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-28 | Iniziato | Stephens | Overweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-30 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Responsive Playbooks and the CADL Inflection - Stock Traders Daily
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy - Investing.com
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk - TipRanks
Small cap wrap: 374Water, Ideal Power, Northstar Gold, Candel Therapeutics… - Proactive financial news
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - finance.yahoo.com
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Bitget
Candel Therapeutics, Inc. announces financial results for the fourth quarter and full year of fiscal 2025, along with recent strategic updates. - Bitget
BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million - TradingView
Tech Rally: Is Candel Therapeutics Inc stock suitable for long term investing2026 Momentum Check & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research - MarketBeat
Candel Therapeutics Presents New Data From Phase 3 Trial Of Aglatimagene Besadenovec In Localized Prostate Cancer - marketscreener.com
Candel Therapeutics Back On The Radar As Prostate And Lung Cancer Trial Catalysts Approach - RTTNews
Candel Therapeutics to present Phase 3 prostate cancer data at AUA 2026 - Proactive Investors
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - Bitget
Paradigm-shifting prostate cancer trial data to debut at AUA 2026 - Stock Titan
Gainers Report: How Candel Therapeutics Inc. stock compares to market leadersWeekly Market Report & Growth Focused Investment Plans - Naître et grandir
Moving Averages: Will Candel Therapeutics Inc. stock outperform Nasdaq indexJuly 2025 Selloffs & Smart Allocation Stock Tips - Naître et grandir
Candel Therapeutics (CADL) Projected to Post Earnings on Thursday - MarketBeat
CADL SEC FilingsCandel Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Candel Therapeutics, Inc. showcases linoserpaturev immunotherapy progress in recurrent glioblastoma case - Traders Union
United StatesGoodwin Guides Candel Therapeutics On $100 Million Public Offering And $100 Millon Royalty Funding Agreement With RTW - Mondaq
CADL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Candel Therapeutics CEO to present progress on immunotherapies at TD Cowen Health Care Conference - Traders Union
New Candel Therapeutics hire gets 20,000 stock options at $5.25 - Stock Titan
CADL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Hedge Fund and Insider Trading News: David Tepper, Steve Cohen, Ray Dalio, Brevan Howard, Millennium Management, Citadel Investment Group, Candel Therapeutics Inc (CADL), Meta Platforms Inc (META), and More - Insider Monkey
Candel Therapeutics Insider Bought Shares Worth $2,999,996, According to a Recent SEC Filing - marketscreener.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m - Investing.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m By Investing.com - Investing.com Australia
Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares - MarketBeat
Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust - Stock Titan
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 259% Potential Upside in Biotech - DirectorsTalk Interviews
Candel Therapeutics, Inc. unveils science behind CAN-2409 driving durable tumor immune response - Traders Union
Candel Therapeutics CEO to present at TD Cowen health care conference on March 3 - Proactive financial news
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - Bitget
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston - The Manila Times
Candel Therapeutics CEO to speak at TD Cowen Boston conference - Stock Titan
Candel Therapeutics Announces Equity Offering to Fund CAN-2409 - The Globe and Mail
Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds - TradingView
Candel Therapeutics (NASDAQ: CADL) prices $100M common stock sale - Stock Titan
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com
Candel Therapeutics Prices $100M Public Offering - Intellectia AI
Candel Therapeutics Faces Market Reaction Post-Secondary Offering - StocksToTrade
Candel Therapeutics’ Stock Offering Sees Market Reaction - timothysykes.com
Candel Therapeutics Prices $100 Million Share Offering - Intellectia AI
Candel Therapeutics Faces Mixed Sentiments After Secondary Offering Announcement - StocksToTrade
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Candel Therapeutics files for offering of 18.3 mln shares of common stock - marketscreener.com
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):